Revenue
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
vTv Therapeutics Inc. (VTVT)
Price$33.35Cached quote
Net income
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total cash / debt
CashTotal debt
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $1.0M | $0 | $2.0M | $4.0M | $6.4M | $2.8M | $12.4M | $291,000 | $634,000 | $519,000 | $1.5M | $976,000 |
| Research & development | $17.9M | $11.5M | $13.6M | $12.4M | $13.3M | $11.0M | $15.1M | $23.0M | $39.6M | $45.0M | $27.2M | $17.4M | $22.3M |
| Operating expenses | $32.8M | $25.2M | $25.5M | $24.6M | $25.7M | $18.3M | $23.7M | $32.3M | $51.0M | $55.7M | $38.7M | $30.4M | $36.8M |
| Operating income | −$32.8M | −$24.2M | −$25.5M | −$22.5M | −$21.7M | −$11.9M | −$20.9M | −$19.8M | −$50.7M | −$55.0M | −$38.1M | −$28.9M | −$35.8M |
| Operating margin | — | −2,377.58% | — | −1,116.95% | −540.87% | −184.78% | −755.86% | −159.43% | −17,416.49% | −8,678.23% | −7,349.13% | −1,865.53% | −3,671.41% |
| EBITDA | −$32.8M | −$24.1M | −$25.4M | −$22.4M | −$21.6M | −$11.8M | −$20.9M | −$19.6M | −$50.5M | −$54.8M | −$37.6M | −$28.0M | −$34.7M |
| EBITDA margin | — | −2,368.83% | — | −1,112.39% | −538.65% | −183.32% | −754.45% | −157.68% | −17,348.80% | −8,636.44% | −7,252.60% | −1,809.75% | −3,560.14% |
| Net income | −$27.0M | −$18.5M | −$20.3M | −$19.2M | −$13.0M | −$8.5M | −$13.0M | −$7.9M | −$16.1M | −$16.4M | −$27.5M | −$36.1M | −$48.2M |
| Net profit margin | — | −1,815.34% | — | −949.65% | −324.27% | −132.51% | −471.92% | −63.62% | −5,547.77% | −2,579.18% | −5,298.27% | −2,330.60% | −4,938.83% |
| Basic EPSper basic share | -$3.20 | -$3.20 | -$9.71 | -$10.40 | — | — | — | — | — | — | — | — | — |
| Diluted EPSper diluted share | -$3.20 | -$3.20 | -$9.71 | -$10.40 | — | — | — | — | — | — | — | — | — |
Owners
Reported shareholders
≈9.96%of listed shares
SEKHRI PAUL J392.21K shares · Feb 17, 2026
View holders
| Holder | % owned |
|---|---|
SEKHRI PAUL J | ≈9.96%392.21K shares |
AKKARAJU SRINIVAS | ≈7.94%312.78K shares |
SAMSARA BIOCAPITAL, LLC | 7.58%298.5K shares |
MILLENNIUM MANAGEMENT LLC | 6.85%269.87K shares |
FMR LLC | 6.61%260.39K shares |
Samsara BioCapital, L.P. / Samsara BioCapital GP, LLC | ≈5.25%206.78K shares |
Siren, L.L.C. | 4.14%163K shares |
BAKER BROS. ADVISORS LP | 3.77%148.31K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 2.40%94.46K shares |
Trails Edge Capital Partners, LP | 2.16%85.19K shares |
Aisling Capital Management LP | 1.27%50K shares |
MARSHALL WACE, LLP | 1.00%39.56K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.82%32.47K shares |
RENAISSANCE TECHNOLOGIES LLC | 0.44%17.45K shares |
VANGUARD FIDUCIARY TRUST CO | 0.41%16.24K shares |
BlackRock, Inc. | 0.37%14.73K shares |
JANE STREET GROUP, LLC | 0.35%13.7K shares |
STATE STREET CORP | 0.31%12.27K shares |
TWO SIGMA INVESTMENTS, LP | 0.29%11.49K shares |
Verdad Advisers, LP | 0.23%9K shares |
Percentages use 3.94M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Nov 18, 2024Form 4 · 10b5-1 | SEKHRI PAUL JPres, CEO and Exec Chairperson | BuyClass A Common Stock | 1.8K | $16.96 | $31.3K | 5.0K |
| Nov 15, 2024Form 4 · 10b5-1 | SEKHRI PAUL JPres, CEO and Exec Chairperson | BuyClass A Common Stock | 1.8K | $16.88 | $30.0K | 3.2K |
| Nov 15, 2024Form 4 · 10b5-1 | SEKHRI PAUL JPres, CEO and Exec Chairperson | BuyClass A Common Stock | 1.4K | $16.35 | $22.5K | 1.4K |